Jonathan Solomon, MD
Ophthalmology · Greenbelt, MDNPI 1497744205
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Lensar, Inc. accounts for 63.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $26,937 and has fallen 82.8% since, to $4,634 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $370.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$66K
- Carl Zeiss Meditec, Inc.$9K
- Sight Sciences, Inc.$8K
- AbbVie$5K
- Eyepoint US, Inc.$4K
- Ivantis, Inc$3K
- plus $10K from 26 others
Across 14 payments — averaging $7679.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$60K
- Carl Zeiss Meditec Production LLC$25K
- Oyster Point Pharma, Inc.$19K
- Bausch Health US, LLC$3K
- AbbVie$749
What the payments were for
- Consulting fees$54,33052%
- Speaking & faculty fees$31,82631%
- Travel & lodging$7261%
- Food & beverage$16,09315%
- Education$1,0501%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 16 | $66,019 |
| Carl Zeiss Meditec, Inc. | 16 | $8,923 |
| Sight Sciences, Inc. | 26 | $8,467 |
| AbbVie(2 entities) | 69 | $4,568 |
| Eyepoint US, Inc. | 4 | $3,565 |
| Ivantis, Inc | 4 | $2,660 |
| Beaver-visitec International, Inc. | 4 | $2,454 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $2,040 |
| NEW World Medical,inc. | 6 | $1,527 |
| Alcon | 16 | $560 |
| Sun Pharmaceutical Industries Inc. | 19 | $470 |
| Glaukos Corporation | 6 | $408 |
| Rayner Intraocular Lenses Limited | 3 | $339 |
| Novartis | 18 | $330 |
| Biotissue Holdings Inc. | 2 | $215 |
| Harrow Eye, LLC | 7 | $204 |
| Oyster Point Pharma, Inc. | 10 | $202 |
| Bausch & Lomb Americas Inc. | 9 | $186 |
| Tarsus Pharmaceuticals, Inc. | 4 | $149 |
| Amgen(2 entities) | 6 | $142 |
| Leica Microsystems Inc. | 1 | $115 |
| Rxsight Inc | 3 | $94 |
| Kala Pharmaceuticals, Inc. | 4 | $84 |
| Dompe US, Inc. | 3 | $74 |
| Staar Surgical Company | 2 | $72 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $62 |
| Ocular Therapeutix, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Oasis Medical, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$65,979
- OMNI$6,242
- CIRRUS HD-OCT$4,550
- VisuMax$3,830
- DEXYCU$3,500
- Cataract Suite$3,150
- Hydrus Microstent$2,633
- OMNI(R) SURGICAL SYSTEM (US)$1,750
- Tecnis Symfony IOL$1,500
- IOLMaster 700$1,421
- OPMI Lumera 700$1,400
- VERACITY SURGICAL$1,360
- Ahmed Glaucoma Valve$1,199
- Kahook Dual Blade$1,199
- QUATERA 700$801
- CIRRUS 6000 with AngioPlex$680
- CLARUS$680
- FORUM Glaucoma Workplace$680
- Humphrey Field Analyzer (HFA3)$680
- Retina Workplace$680
How this compares
$104,069 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 41 | $71,689 |
| RestasisCyclosporine | 11 | $16,189 |
| Prednisolone Acetate | 182 | $12,628 |
| MoxifloxacinMoxifloxacin Hcl | 151 | $3,126 |
| Ketorolac Tromethamine | 116 | $2,199 |
| Brimonidine Tartrate | 15 | $996 |
| Latanoprost | 29 | $362 |
| ErythromycinErythromycin Base | 11 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $186 | $71,68941 claims |
| AbbVieRestasis | $4,568 | $16,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Greenbelt
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Allen HuHagerstown$379K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
- Neil BresslerBaltimore$265K
- Scott LaborwitTowson$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.